A Pilot Study to Analyse the Effectiveness of Dendritic Cell Immunotherapy in Ovarian Cancer
Author(s):
Jamal A Khan, Sharmin Yaqin, Rakesh Reddy, Raman Yadav, Monika Deswal* and Shahzad Hoda
After breast and cervical cancers, ovarian cancer ranks third among gynaecological cancers in terms of prevalence. Those with metastatic ovarian cancer have a five-year survival rate of less than 27%. The likelihood of survival is almost 90% for people with confined or primary illness. In reality, only 20% of cancers are found at that early stage. Others were found after the tumour had already invaded the whole peritoneal cavity. Chemotherapy is ineffective against cancer cells at this stage, resulting in low survival rates and high recurrence rates. The ability of immune cells to eradicate cancerous cells is inhibited by ovarian tumours’ severe immunosuppressive nature and many immune-suppressing mechanisms. In addition to conventional therapy, dendritic cell immunotherapy has been shown to be one of the most effective ways to prevent recurrence and improve overall survival by utilising the immune system’s capacity to attack malignant cancers. We conducted a study on individuals with ovarian cancer while keeping in mind the tumour microenvironment and dendritic cell functionality in ovarian cancer. Individualized autologous dendritic cell immunotherapy was given to each patient. With regard to the response rate and overall survival, the study’s findings and ramifications are examined.
